Low-coverage whole-genome sequencing of cancer and healthy plasma circulating DNA
Ontology highlight
ABSTRACT:
PROVIDER: EGAS00001007593 | EGA |
REPOSITORIES: EGA
Similar Datasets
Project description:Plasma samples from patients with melanoma (stage II/III/IV) and breast cancer (stage IV) as well as healthy individuals were subjected to low-coverage whole-genome sequencing (less than 10x average depth). This dataset contains raw fastq files from 39 breast cancer, 127 melanoma and 42 healthy control plasma samples.
| EGAD00001011817 | EGA
Project description:Contain data of 2 studies
1: 82 nodal stage 1 FL cases and 139 stage III/IV cases
2: 44 watch and wait stage III/IV and 46 Immediate treatment stage III/IV
targeted sequencing data of 369 genes and 12 translocation regions
whole genome shallow sequencing data
| EGAS00001005755 | EGA
Project description:Breast cancer (BCa) is the leading cause of death by cancer in women worldwide. Early diagnosis is improving the survival of BCa patients but more sensitive and specific tools are still necessary. We propose the use of miRNAs as a biomarker alternative in BCa diagnosis. MiRNAs are small non-coding RNAs that regulate gene expression. Circulating miRNAs can be detected in body fluids. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. Furthermore, metabolic syndrome (MeS) is a risk factor for BCa. Molecular mechanisms underlaying this association have not been fully elucidated. The aim of this work was to identify the circulating miRNAs in plasma of BCa patients and healthy donors with or without clinical features linked to MeS. MiRNAs were isolated from plasma of woman. BCa patients (N=30) were distributed into 5 clusters, according with their BCa stage: i) stages 0 and IA, ii) stage IIA, iii) stage IIB, iv) stage IIIA, and v) stages IIIB, IIIC and IV. Healthy women (HD) (N=36) were recruited and divided in two groups, control or MeS-linked disease (MeSL) when presented two or more of these conditions: BMI≥25.00 kg/m2, waist diameter≥82 cm or high blood pressure (systolic≥120, diastolic≥ 80). We hybridized miRNAs of each group using GeneChip® miRNA 4.0 Array (Affymetrix). miRNA expression profile was also determined by miRNA sequencing from 6 BC patients and 4 HD. Data analysis revealed 11 miRNAs upregulated in the plasma from BCa patients compared to HD. Meanwhile, 24 miRNAs were altered in plasma of women with MeSL compared to control.
2024-08-31 | GSE235353 | GEO
Project description:Breast cancer (BCa) is the leading cause of death by cancer in women worldwide. Early diagnosis is improving the survival of BCa patients but more sensitive and specific tools are still necessary. We propose the use of miRNAs as a biomarker alternative in BCa diagnosis. MiRNAs are small non-coding RNAs that regulate gene expression. Circulating miRNAs can be detected in body fluids. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. Furthermore, metabolic syndrome (MeS) is a risk factor for BCa. Molecular mechanisms underlaying this association have not been fully elucidated. The aim of this work was to identify the circulating miRNAs in plasma of BCa patients and healthy donors with or without clinical features linked to MeS. MiRNAs were isolated from plasma of woman. BCa patients (N=30) were distributed into 5 clusters, according with their BCa stage: i) stages 0 and IA, ii) stage IIA, iii) stage IIB, iv) stage IIIA, and v) stages IIIB, IIIC and IV. Healthy women (HD) (N=36) were recruited and divided in two groups, control or MeS-linked disease (MeSL) when presented two or more of these conditions: BMI≥25.00 kg/m2, waist diameter≥82 cm or high blood pressure (systolic≥120, diastolic≥ 80). We hybridized miRNAs of each group using GeneChip® miRNA 4.0 Array (Affymetrix). miRNA expression profile was also determined by miRNA sequencing from 6 BC patients and 4 HD. Data analysis revealed 11 miRNAs upregulated in the plasma from BCa patients compared to HD. Meanwhile, 24 miRNAs were altered in plasma of women with MeSL compared to control.
2024-08-31 | GSE235354 | GEO
Project description:A secreted factor in bone marrow associated with metastatic gastric cancer was indentified through expression profiling in bone marrow of stage III and stage IV gastric adenocarcinoma.
2013-10-22 | GSE41801 | GEO
Project description:A secreted factor in bone marrow associated with metastatic gastric cancer was indentified through expression profiling in bone marrow of stage III and stage IV gastric adenocarcinoma. In the study presented here, bone marrow samples from patients with stage III or stage IV gastric adenocarcinoma were used to acquire expression profiles.
2013-10-22 | E-GEOD-41801 | biostudies-arrayexpress
Project description:To identifiy stage-dependent genes in Sertoli cells, we performed expression microarray analysis of the adult whole testes, cultured primary Sertoli cells, Sertoli cells directly isolated from wild-type and Nanos3 (germ-less) testes,seminiferous tubules at stages I-III, IV-VI, VII-VIII and IX-XII. Next to examine the relationship between stage-dependent gene expression change and retinoic acid signaling, we performed expression microarray analysis of the cultured primary Sertoli cells treated with retinoic acid and stage-specific seminiferous tubules injected with lentivirus containing Venus or dominat negative form of RARa, a dominant receptor for retinoic acid in Sertoli cells.
2012-07-01 | GSE34758 | GEO
Project description:To identify genes that are drought-responsive we conducted drought (soil water depletion) experiments on 3-month-old *P*. *trichocarpa *clonal plants. The plants undergo five different stages based on the appearance of their shoots and leaves during the drought experiments. Stage I: The shoot and leaves are green, and the leaves are well-spread. Stage II: The leaves are droopy. Stage III: The shoot is droopy, and the leaves are partially dry. Stage IV: The leaves are brown and totally dry. Stage V: The shoot is brown. With fully irrigation, the soil water content is 74% and the xylem water content is 80.6%. Plants in Stage III (Day 5) are under a mild drought state. The soil and xylem water content in Stage III dropped to 33% and 75.3%, respectively. Stage IV (Day 6-10) is a severe drought state where the soil and xylem water content continued decreasing to 29% and 74.3%, respectively in Day 7. The stressed plants from Stage I-IV could all recover in 3 days after rehydration, but the plants in Stage V could not recover after rehydration.
2018-12-27 | GSE79401 | GEO
Project description:Plasmodium falciparum gametocytes can often show differential drug responses depending on their stage of development. Here, the transcriptomic response of early stage (Stage II-III) and late stage (Stage IV-V) gametocytes was evaluated following treatment with chemical compounds that show differential killing activity between early and late-stage gametocytes.
2021-02-19 | GSE167068 | GEO
Project description:Most (70%) epithelial ovarian cancers (EOCs) are diagnosed late. Non-invasive biomarkers that facilitate disease detection and predict outcome are needed. The microRNAs (miRNAs) represent a new class of biomarkers. This study was to identify and validate plasma miRNAs as biomarkers in EOC. We evaluated plasma samples of 360 EOC patients and 200 healthy controls from two institutions. All samples were grouped into screening, training and validation sets. We scanned the circulating plasma miRNAs by TaqMan low-density array in the screening set and identified/validated miRNA markers by real-time polymerase chain reaction assay in the training set. Receiver operating characteristic and logistic regression analyses established the diagnostic miRNA panel, which were confirmed in the validationsets. We found higher plasma miR-205 and lower let-7f expression in cases than in controls. MiR-205 and let-7f together provided high diagnostic accuracy for EOC, especially in patients with stage I disease. The combination of these two miRNAs and carbohydrate antigen-125 (CA-125) further improved the accuracy of detection. MiR-483-5p expression was elevated in stages III and IV compared with in stages I and II, which was consistent with its expression pattern in tumor tissues. Furthermore, lower levels of let-7f were predictive of poor prognosis in EOC patients. Our findings indicate that plasma miR-205 and let-7f are biomarkers for ovarian cancer detection that complement CA-125; let-7f may be predictive of ovarian cancer prognosis. We designed a multi-stage, retrospective, nested case-control study to determine whether serum miRNA profiles can be used to predict EOC development. All samples were grouped into screening, training, and validation sets. A total of 560 plasma samples (360 cases and 200 controls) were obtained from Tianjin Medical University Cancer Institute and Hospital (TCIH) and Cancer Center of Nanjing Medical University. The cases and controls were well matched for age. The International Federation of Gynaecology and Obstetrics (FIGO) staging system was used to stage cases. All patients and controls were genetically unrelated, ethnic Han Chinese women who were permanent residents of the urban area of Tianjin and Nanjing. Controls with cardiovascular, respiratory, digestive, urinary, reproductive, and endocrine diseases were excluded. The study protocols were approved by the Tianjin and Nanjing Center review committees. In screening set, to detect generalizable miRNA signatures, we pooled serum samples of 10 early-stage cases (stage I), 10 late-stage cases (stage IIIc-IV), and 10 healthy controls, respectively, and analyzed these three pool samples using a TaqMan low-density array (TLDA set 2.0, Applied Biosystems) chip screening in the discovery stage. In training set, the miRNAs identified in the screening set were validated using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) on individual plasma samples of 76 EOC patients and 30 normal controls. In validation set, the validation set comprised a two-phase process. Promising associations from the screening and training set were evaluated in the validation phase I set, comprising 134 cases and 70 controls from Tianjin Center. The validation phase II set included samples of 77 EOC cases and 50 normal controls were from Tianjin Center and 73 EOC cases and 50 normal controls were from Nanjing Center.
2013-08-30 | E-GEOD-50472 | biostudies-arrayexpress